RxDoctor Payments Data

Omer Yilmaz, MD

Anatomic Pathology & Clinical Pathology · Boston, MANPI 1417116864

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $22,770 of the $27,672 with a category attached, or 82.3%. Merck accounts for 78.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $21,714 and has fallen 84.0% since, to $3,468 in 2025. Among anatomic pathology & clinical pathology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,672in general payments, 2019–2025

Across 23 payments — averaging $1203.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$22K
  • Genentech, Inc.$3K
  • Boehringer Ingelheim$2K
$397,945in research payments, 2019–2025

Across 3 payments — averaging $132,648 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Exelixis Inc.$398K

What the payments were for

  • Consulting fees$22,77082%
  • Travel & lodging$4,52116%
  • Food & beverage$3811%

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck18$21,714
Genentech, Inc.4$3,468
Boehringer Ingelheim1$2,490

How this compares

$27,672 in reported general payments places this provider in the 95th percentile of 196 anatomic pathology & clinical pathology providers in Massachusetts.

See all anatomic pathology & clinical pathology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$42,469
Medicare patients
408
Services billed
1,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →